Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

August 31, 2008

Conditions

Lymphoma

Interventions

DRUG

BI 2536

Trial Locations (4)

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C.

UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha

M. D. Anderson Cancer Center at University of Texas, Houston